Levofloxacin-d8 is intended for use as an internal standard for the quantification of levofloxacin by GC- or LC-MS. Levofloxacin is a fluoroquinolone antibiotic and the active stereoisomer of ofloxacin .1 It is active against S. aureus, S. epidermidis, B. subtilis, E. coli, P. aeruginosa, and K. pneumoniae (MICs = 0.25, 0.25, 0.5, 0.03, 4, and 0.25 μg/ml, respectively).2 Levofloxacin inhibits S. aureus DNA gyrase and topoisomerase IV (IC50s = 8.06 and 9.81 μg/ml, respectively).3 It eliminates infection in rat models of endocarditis caused by methicillin-sensitive or -resistant S. aureus.4 Formulations containing levofloxacin have been used in the treatment of various bacterial infections.
1.Norrby, S.R.LevofloxacinExpert Opin. Pharmacother.1(1)109-119(1999) 2.Mohammadhosseini, N., Alipanahi, Z., Alipour, E., et al.Synthesis and antibacterial activity of novel levofloxacin derivatives containing a substituted thienylethyl moiety.Daru.20(1)(2012) 3.Takei, M., Fukuda, H., Kishii, R., et al.Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibitionAntimicrob. Agents Chemother.45(12)3544-3547(2001) 4.Entenza, J.M., Vouillamoz, J., Glauser, M.P., et al.Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureusAntimicrob. Agents Chemother.41(8)1662-1667(1997)